<DOC>
	<DOC>NCT02324972</DOC>
	<brief_summary>The primary objective of this study is to evaluate the effect of 12 weeks of treatment with once daily administration of AQX-1125 compared to placebo on change from baseline in Target Lesion Symptom Score in subjects with mild to moderate atopic dermatitis</brief_summary>
	<brief_title>Pilot Efficacy and Safety Study of AQX-1125 in Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>1. Male or female aged from 18 to 65 years old 2. Confirmed clinical diagnosis of active atopic dermatitis (AD) 3. At least a 6 months history of atopic dermatitis. 4. Body Surface Area (BSA) covered with atopic dermatitis of 1% or more 5. Mild or moderate atopic dermatitis (IGA score of 2 or 3). 6. TLSS of 5 or more at Day 0. 7. Subject must use a nonmedicated emollient daily for at least (â‰¥) 7 days prior to Day 0 and should continue using that same emollient, at the same frequency, throughout the study. 1. Female subject who is pregnant or breastfeeding 2. Unstable or clinically infected atopic dermatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Atopic dermatitis</keyword>
	<keyword>Eczema</keyword>
	<keyword>AD</keyword>
	<keyword>AQX-1125</keyword>
	<keyword>SHIP1</keyword>
</DOC>